Study Linking Cannabis Use And Increased Risk Of Metabolic Syndrome Is Inconsistent With Prior Data

Atlanta, GA: The findings of a recent, well-publicized study correlating long-term cannabis use with a slightly increased risk of metabolic syndrome are inconsistent with those of several prior observational studies. Metabolic syndrome (MetS) is a constellation of risk factors linked with an increased likelihood of cardiovascular diseases such as heart attack and stroke.

Investigators at the Georgia State University School of Public Health assessed the association between subjects’ duration of cannabis use and MetS in a cohort of 3,051 adults who participated in the National Health and Nutrition Examination Survey (NHANES) during the years 2011 and 2012.

Researchers reported that subjects’ cannabis use history was correlated with a “small, yet consistent increase in odds” for hypertension, obesity and other MetS risk factors. For many factors, the data showed “an initial decrease in values but [then an] eventual increase.” Authors of the study were unable to control for subjects’ diet, an important risk factor for MetS.

They concluded, “Extended duration of marijuana use could possibly increase the risk for the development of metabolic syndrome. … Longitudinal research is required to define the true relationship between marijuana use and metabolic syndrome.”

Researchers acknowledged that their findings are largely inconsistent with those of prior studies. Specifically, a 2016 study involving a significantly larger cohort of NHANES participants reported that “current marijuana use is associated with lower odds of metabolic syndrome.”

Several other observational trials have similarly reported that those with a cannabis use history are less likely to be obese, possess lower BMI, and are less likely to suffer from adult onset diabetes as compared to non-users. A 2017 longitudinal study reported that those who consume cannabis long-term suffer no greater likelihood of cardiovascular disease by middle age than do those with no history of use.

Recent clinical trials data also finds that the administration of specific cannabinoids, such as CBD and THC-V, are positively associated with reductions in blood pressure and blood sugar levels.

For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Relationship between years of marijuana use and the four main diagnostic criteria for metabolic syndrome among United States adults,” appears in the Journal of Addiction Research and Therapy.
P.S. Our efforts are supported by thousands of people throughout the country as we work to advance marijuana reform in all 50 states and the federal level. Can you kick in $5, $10 or $20 a month to help us keep going?
P.P.S. Have you gotten your ticket for the 2017 NORML D.C. Conference and Lobby Day yet? Register and join the fight to end federal marijuana prohibition in Washington, DC September 10th-12th.
NORML and the NORML Foundation: 1100 H Street NW, Suite 830, Washington DC, 20005
Tel: (202) 483-5500 • Fax: (202) 483-0057 • Email: norml@norml.org

Donate Now
Donate Now

#TakeAction
Tell AAA To Stop Lying About Legalization
From the blog
Colorado: Tax Revenue From The Legal Cannabis Industry Surpasses Half-Billion Dollars Details
07/20/17 7:39pm UTC
WATCH: Marijuana in the Halls of Congress Details
07/19/17 4:57pm UTC
Uruguay: Retail Cannabis Sales Begin Today Details
07/19/17 1:04pm UTC
New Hampshire: Marijuana Decriminalization Measure Signed Into Law Details
07/18/17 11:52pm UTC
Tell AAA To Stop Lying About Legalization Details
07/18/17 10:07pm UTC

NORML on the Hill
NORML On The Hill

Pot For Health
Pot For Health

NORML PSA
NORML PSA

Find a Lawyer
Find a Lawyer
Other Ways to Help
Write to Elected Officials
Advertise
NORML Store
Volunteer
Networking
Facebook
Twitter
Blog
Chapt

Leave a Reply

Your email address will not be published. Required fields are marked *